Author: Willoughby, James E. ; Kim, Raymond ; Lux, Christian A. ; Douglas, Richard G. ; Koefoed, Arne ; Biswas, Kristi ; Broderick, David ; Mackenzie, Brett Wagner ; Hale, Samuel J. M.

Key points

Novel topical therapeutics require extensive pre‐clinical testing to assess efficacy and safety.

Antibiofilm or immunosuppressant agents can utilize ex vivo models to measure ciliotoxicity.

Agents that are found to be effective and non‐toxic ex vivo warrant further investigation in vivo.

01 Sep 2024·European review for medical and pharmacological sciences

A systematic review of recent advances in urinary tract infection interventions and treatment technology.

Review

Author: Mukherjee, T K ; Almutairy, A F ; Mohammad, A A S ; Akhtar, M S ; Alam, P ; Alam, M S ; Anwar, M J ; Nazmi, A S

OBJECTIVEUrinary tract infection is one of the most common extraintestinal infectious diseases encountered in clinics. It affects both genders and all age groups and constitutes a major health issue in clinical practice worldwide. Uropathogens often develop resistance to therapeutic agents, creating a formidable challenge for physicians to treat these infections. The goal of the current review is to provide current information on therapeutic advancements and interventions in the treatment of urinary tract infections.MATERIALS AND METHODSDatabases like MEDLINE, PubMed, and ClinicalTrials.gov were used as search engines to collect the relevant articles, and the required information was extracted.RESULTSResearch data suggest an increasing prevalence of pathogenic strains that are resistant to standard antimicrobial regimens recommended for the treatment of urinary tract infections. Targeted therapies for urinary tract infections, such as mannosides and pilicides, as well as vaccinations against uropathogenic Escherichia coli, have been developed recently. The efficacy of other strategies like iontophoresis, hydrogel-coated catheters, and antibiofilm therapy is also investigated. Clinical trials conducted between 2014 and 2019 show a rise in interest in a variety of therapies, highlighting the need for a thorough strategy to treat urinary tract infections, particularly in populations of women.CONCLUSIONSAntimicrobial-resistant strains of Escherichia coli are becoming more common in urinary tract infections, which have led to the development of targeted medicines such as mannosides and pilicides, as well as immunizations against the pathogenic Escherichia coli strains. There is continuing research into alternate approaches, such as hydrogel-coated catheters, antibiofilm therapy, and iontophoresis. Clinical trials conducted between 2014 and 2019 showed a rise in interest in these different treatment approaches.

01 Aug 2024·Microbial Pathogenesis

Antibiofilm activity of promethazine against ESBL-producing strains of Escherichia coli in urinary catheters

Article

Author: de Queiroz, Matheus Victor Feitosa ; Ferreira, Thais Lima ; de Lima, Elaine Aires ; Cabral, Vitória Pessoa de Farias ; da Silva, Cecília Rocha ; Barbosa, Sarah Alves ; Nobre Júnior, Hélio Vitoriano ; Rodrigues, Daniel Sampaio ; Moreira, Lara Elloyse Almeida ; de Andrade Neto, João Batista ; Valente Sá, Livia Gurgel do Amaral ; Barbosa, Amanda Dias ; da Costa, Érica Rayanne Mota ; Pinheiro, Dávylla Rênnia Saldanha

The bacterium Escherichia coli is one of the main causes of urinary tract infections. The formation of bacterial biofilms, especially associated with the use of urinary catheters, contributes to the establishment of recurrent infections and the development of resistance to treatment. Strains of E. coli that produce extended-spectrum beta-lactamases (ESBL) have a greater ability to form biofilms. In addition, there is a lack of drugs available in the market with antibiofilm activity. Promethazine (PMZ) is an antihistamine known to have antimicrobial activity against different pathogens, including in the form of biofilms, but there are still few studies of its activity against ESBL E. coli biofilms. The aim of this study was to evaluate the antimicrobial activity of PMZ against ESBL E. coli biofilms, as well as to assess the application of this drug as a biofilm prevention agent in urinary catheters. To this end, the minimum inhibitory concentration and minimum bactericidal concentration of PMZ in ESBL E. coli strains were determined using the broth microdilution assay and tolerance level measurement. The activity of PMZ against the cell viability of the in vitro biofilm formation of ESBL E. coli was analyzed by the MTT colorimetric assay and its ability to prevent biofilm formation when impregnated in a urinary catheter was investigated by counting colony-forming units (CFU) and confirmed by scanning electron microscopy (SEM). PMZ showed bactericidal activity and significantly reduced (p < 0.05) the viability of the biofilm being formed by ESBL E. coli at concentrations of 256 and 512 μg/ml, as well as preventing the formation of biofilm on urinary catheters at concentrations starting at 512 μg/ml by reducing the number of CFUs, as also observed by SEM. Thus, PMZ is a promising candidate to prevent the formation of ESBL E. coli biofilms on abiotic surfaces.

100 Deals associated with BFP-101

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Bone and joint infections	Discovery	FR	Biofilm PharmaStartup	-
Diabetic Foot	Discovery	FR	Biofilm PharmaStartup	-
Staphylococcal Infections	Discovery	FR	Biofilm PharmaStartup	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

BFP-101

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation